Enrolling

SUNRAY-01: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01)

J3M-MC-JZQB -

The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C.

Enter your city or zip code to find the nearest site

See if You May Qualify

Answer a few questions to see if you meet key criteria for this study.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Non-Small Cell Lung Cancer
What the trial is testing?
LY3537982, Pemetrexed, Pembrolizumab, Cisplatin, Carboplatin
Could I receive a Placebo?
Yes
Enrollment Goal
1016
Trial Dates
Dec 21, 2023 - Oct 2029
How long will I be in the trial?
Study participation, including follow-up, could last up to 3 years.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Have non-small cell lung cancer that is advanced or has spread to another part(s) of the body

  • Have cancer with a change in the KRAS G12C gene

  • Have a known programmed death-ligand 1 (PD-L1) expression of 0-100%.  PD-L1 expression may predict how well the body responds to some types of treatment

  • Be able to swallow capsules and/or tablets

  • Be well enough to walk and do light work

Participants Must Not:

  • Have other types of changes in genes such as EGFR, ALK, BRAF (V600E), HER2, MET (exon 14), ROS1, RET, or NTRK1/2/ that may be targeted treatments

  • Have cancer that can be cured with treatments that target a specific part of the body (like surgery or radiation)

  • Have an active infection or any serious medical conditions (other than cancer)

  • Have active heart disease causing symptoms; or, history of heart attack or chest pain within 6 months of starting the study

  • Have a known history of allergic reaction to components of the study drug (LY3537982), pembrolizumab, pemetrexed or platinum containing drugs

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources